Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. reports developments in clinical-stage immunology therapeutics and immune-modulating biologics. Company updates center on its Immuno-STAT platform, the autoimmune and inflammatory disease candidate CUE-401, a clinical-stage dual-mechanism anti-IgE antibody for allergic diseases, and collaboration activity involving B cell depletion programs such as CUE-501.
Recurring news also covers leadership changes, inducement equity awards, shareholder-approved capital actions, research presentations, milestone payments, licensing activity, and other corporate matters tied to Cue Biopharma's Nasdaq-listed common stock and clinical-stage operating model.
Cue Biopharma announced its participation in the Jefferies Healthcare Conference scheduled for June 8-10, 2022. The company will present updates on its lead candidate, CUE-101, currently in a Phase 1b trial for HPV16+ head and neck cancer, and its second candidate, CUE-102, which received FDA approval for an IND application. CUE-102 will undergo Phase 1 trials for WT1-positive cancers. The presentation is set for June 10 at 1:45 p.m. EDT, with webcasts available for 30 days.
BOSTON, May 26, 2022 – Cue Biopharma (Nasdaq: CUE) announced a poster presentation at the ASCO Annual Meeting from June 3-7 in Chicago. The poster will showcase interim clinical data on CUE-101, an IL-2-based therapeutic for recurrent/metastatic HPV16+ head and neck cancer, both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®). The presentation is scheduled for June 6, 2022, by Dr. Christine Chung of Moffitt Cancer Center. Interested parties can view the poster on Cue Biopharma’s website after the event.
On May 11, 2022, Cue Biopharma announced that the FDA accepted its IND application for CUE-102, initiating a Phase 1 trial for the treatment of WT1-positive recurrent/metastatic cancers, including gastric and pancreatic cancers. The trial will start at a dose of 1 mg/kg, which is expected to streamline the dose escalation process, potentially reducing time and costs. CUE-102 builds on the CUE-100 series biologics, which selectively engage T cells, and follows the encouraging results from the CUE-101 trial.
Cue Biopharma (CUE) reported Q1 2022 financial results, highlighting a cash runway extension with $23.6 million raised through the sale of 3.6 million shares. Collaboration revenue decreased to $1.0 million from $1.6 million year-over-year. R&D expenses rose to $10.1 million, with total operating expenses at $15.2 million, leading to a net loss of $14.3 million. Clinical advancements include the enrollment of 20 patients for CUE-101, demonstrating a favorable tolerability profile in HPV16-driven cancers. The company continues to progress its Immuno-STAT platform.
Cue Biopharma, a clinical-stage biopharmaceutical company, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 11:20 a.m. EDT. The discussion will cover clinical updates on CUE-101, targeting HPV+ recurrent/metastatic head and neck cancer. The company also plans to highlight milestones for its pipeline, including CUE-102, with an IND filing expected by the end of Q1 2022. The webcast will be available live and archived for 30 days on their website.
Cue Biopharma (Nasdaq: CUE) announced its participation in the Festival of Biologics World Immunotherapy Congress in San Diego from March 9-11, 2022. Dr. Matteo Levisetti will present on the Immuno-STAT™ platform and recent clinical trial data for CUE-101, targeting HPV+ recurrent/metastatic head and neck cancer. The data illustrates favorable tolerability and promising anti-tumor activity. Cue Biopharma aims to differentiate its IL-2 based therapies with CUE-101's selective targeting mechanism, indicating potential alterations in cancer treatment.
Cue Biopharma (CUE) has announced a presentation at the Biophysical Society Annual Meeting, highlighting a collaboration with the University of Oxford's Dr. Michael Dustin. This study focuses on the mechanisms of IL-2 in T cell immunological synapse formation, particularly regarding its CUE-100 series biologics. Lead candidate CUE-101 aims to enable selective T cell activation, strengthening its potential for treating tumors. The presentation will take place on February 20, 2022, at 1:45 p.m. PST.
Cue Biopharma (CUE) provided a clinical update on its lead candidate CUE-101, currently in a Phase 1b trial for HPV+ recurrent/metastatic head and neck cancer.
Early data from a combination study with KEYTRUDA® revealed positive outcomes, with two patients achieving partial responses and two showing lesion reductions.
Additionally, CUE-101 monotherapy demonstrated a 50% clinical benefit rate, enhancing overall survival rates by selectively stimulating CD8+ T cells.
Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical firm, announced a conference call and webcast for January 26, 2022, at 4:30 p.m. EST to provide updates on its clinical trials, particularly for CUE-101, its lead IL-2 based candidate targeting HPV+ recurrent/metastatic head and neck cancer. The call will discuss recent data from the Phase 1b trial and plans for CUE-102, along with strategic objectives and anticipated milestones. The event will be accessible live and archived on the company’s website.
On January 5, 2022, Cue Biopharma announced a major milestone in its collaboration with LG Chem Life Sciences regarding CUE-102, an Immuno-STAT™ biologic targeted at WT1-expressing cancers. The achievement paves the way for a planned IND submission to the FDA in Q1 2022 and includes a $3 million milestone payment from LG Chem. CEO Daniel Passeri expressed optimism about CUE-102's potential in treating solid tumors and hematologic malignancies. Preclinical data reinforces the versatility of the Immuno-STAT platform, aimed at advancing oncology therapies directly in patients.